CA2746717A1 - Anti-fungal diaper rash creme - Google Patents
Anti-fungal diaper rash creme Download PDFInfo
- Publication number
- CA2746717A1 CA2746717A1 CA2746717A CA2746717A CA2746717A1 CA 2746717 A1 CA2746717 A1 CA 2746717A1 CA 2746717 A CA2746717 A CA 2746717A CA 2746717 A CA2746717 A CA 2746717A CA 2746717 A1 CA2746717 A1 CA 2746717A1
- Authority
- CA
- Canada
- Prior art keywords
- fungal
- emollient base
- diaper rash
- creme
- emollient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An antifungal and diaper rash treatment creme for cells in skin tissue comprising a non--medicinal emollient base, an anti-fungal in the emollient base to treat both obvious fungal infection as well as nonobvious fungal infection associated with diaper rash and a corticosteroid in the emollient base to immediately reduce irritating symptoms of tissue congestion, and to thereby substantially accelerate infection disposition in obvious fungus treatment applications by facilitating penetration of less congested individual cells in the tissue by the anti-fungal.
Description
ANTI-FUNGAL DIAPER RASH CREME
FIELD OF INVENTION
The present invention relates to a treatment for rashes and fungal infections.
More specifically, it relates to a creme, which is effective for the treatment of diaper rash and topical fungal infections.
BACKROUND OF INVENTION
Topical cremes are commonly used to treat fungal infections. However, many patients suffer from advanced topical fungal infections that are accompanied by irritating inflammatory conditions of pain, swelling and itching. Due to unknown and unidentified systemic conditions, a permanent cure is far from instantaneous, and in fact may be illusive for an extended period of time. Particularly, for these patients, in addition to treating fungal infections, it is desirable to treat accompanying inflammatory and irritant conditions of the skin to relieve pain, swelling and itching. The accompanying inflammation and irritation is the primary symptom, and most frequently it is the symptom itself, which is identified by the patient as the unresolved problem.
Diaper rashes are also a common problem encountered in infant and elderly care.
While there are many products that treat rashes, none also reduce the symptoms of the irritation.
There are numerous cremes that have been developed to treat either fungal infections or diaper rashes. However, none of these has proven effective for treating fungal infections, while also treating the inflammatory conditions of pain, swelling and itching that commonly accompany these fungal infections. Accordingly, there is a need for a topical fungal creme that meets this need.
SUMMARY OF THE INVENTION
The present invention relates to an antifungal and diaper rash treatment creme that is effective at treating fungal infections, while also treating the inflammatory conditions of pain, swelling and itching that commonly accompany these fungal infections.
I
The inventors of the present invention have found that one effective treatment for fungal infections is a polyene antifungal drug such as nystatin. Moreover, effective anti-inflammatory treatments include corticosteroids, such as hydrocortisone. It had previously been discovered that when an anti-fungal and an anti-inflammatory were applied consecutively, the combination was not optimally effective. This is because the first treatment prevents the direct absorption of the second treatment. The inventors of the present inventions have found that this problem can be overcome by applying the anti-fungal and the anti-inflammatory treatments in a single application.
The inventors of the present invention also discovered unexpected advantages when utilizing the correct formulation for the topical creme. It has been found that when a topical fungal infection is additionally treated with a corticosteroid, the curing of the infection is substantially and dramatically accelerated. Painful symptoms, which would otherwise persist for more than a few weeks were substantially reduced within 24 hours of application. For example, an individual with athlete's foot with considerable inflammation and discomfort would typically be healed in two to four weeks.
However, by utilizing the creme disclosed by the present invention, it has been found that individuals have been healed in less than two weeks.
The inventors of the present invention have also found that embodiments of the present invention are effective in treating diaper rashes. This is because the anti-fungal component of the present invention targets the fungi found in diaper rashes.
The fecal matter produced by the wearer of the diaper contain infections and the damp warm environment in a diaper is ideal for fungus growth. Commonly known diaper rash cremes do not treat the fungal infections involved with diaper rashes. In fact, many known cremes such as petroleum jelly can actually cover, and then contain the infection on the surface of the skin. Accordingly, a particular embodiment of the present invention includes an antifungal and diaper rash treatment creme for cells in skin tissue comprising:
a) a non-medicinal emollient base;
b) an anti-fungal in the emollient base to treat both obvious fungal infection as well as nonobvious fungal infection associated with diaper rash; and c) a corticosteroid in the emollient base to immediately reduce irritating symptoms of tissue congestion, and to thereby substantially accelerate infection disposition in obvious fungus treatment applications by facilitating penetration of less congested individual cells in the tissue by the anti-fungal.
In another embodiment of the present invention, the antifungal skin and diaper rash treatment creme comprises hydrocortisone in the amount of about to 0.01 to about 2.5 percent by weight of said emollient base and said anti-fungal comprises from about 1 to about 500,000 units of nystatin per gram of said emollient base.
In another embodiment of the present invention, the antifungal skin and diaper rash treatment creme comprises hydrocortisone in the amount of about to 0.05 to about 2.0 percent by weight of said emollient base and said anti-fungal comprises from about 2500 to about 400,000 units of nystatin per gram of said emollient base.
In another embodiment of the present invention, the antifungal skin and diaper rash treatment creme comprises hydrocortisone in the amount of about to 0.1 to about 1.5 percent by weight of said emollient base and said anti-fungal comprises from about 25,000 to about 350,000 units of nystatin per gram of said emollient base.
In another embodiment of the present invention, the antifungal skin and diaper rash treatment creme comprises hydrocortisone in the amount of about to 0.5 to about 1.25 percent by weight of said emollient base and said anti-fungal comprises from about 200,000 to about 300,000 units of nystatin per gram of said emollient base.
In another embodiment of the present invention, the antifungal skin and diaper rash treatment creme comprises hydrocortisone in the amount of about 1.0 percent by weight of said emollient base and said anti-fungal comprises about 250,000 units of nystatin per gram of said emollient base.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to an antifungal and diaper rash treatment creme that is effective at treating fungal infections, while also treating the inflammatory conditions of pain, swelling and itching that commonly accompany these fungal infections.
It will be readily understood that the components of the present invention, as generally described herein, could be arranged and designed in a wide variety of different formulations. Thus, the following more detailed description of the embodiments of the I
compositions or formulations of the present invention are not intended to limit the scope of the invention, as claimed, but are merely representative of the presently preferred embodiments of the invention.
In a particular embodiment of the present invention, an antifungal and diaper rash treatment creme for cells in skin tissue comprises a non-medicinal emollient base, an anti-fungal in the emollient base to treat both obvious fungal infection as well as nonobvious fungal infection associated with diaper rash and a corticosteroid in the emollient base to immediately reduce irritating symptoms of tissue congestion, and to thereby substantially accelerate infection disposition in obvious fungus treatment applications by facilitating penetration of less congested individual cells in the tissue by the anti-fungal.
It is noted that the emollient base might include such non-medicinal ingredients as aluminum hydroxide gel, ceteareith 15, monostearate, methylparaben, PEG-400, perfume, propylene glycol, propylparaben, purified water, simethicone emulsion, sodium hydroxide, sorbitol, titanium dioxide, white petroleum, cetearyl alcohol, ceteth 20, chlorocresol, mineral oil, sodium phosphate and other commonly used agents other than lanolin.
In a particular embodiment of the present invention, the corticosteroid comprises hydrocortisone in the amount of about 0.01 % to about 2.5% b weight of the emollient base and the anti-fungal comprises nystatin in the amount of 1-500,000 units per gram of the emollient base. In a preferred embodiment of the present invention, the hydrocortisone comprises I % of the emollient base, and wherein the nystatin generally comprises 250,000 units per gram of the emollient base. It is intended that in this embodiment, the concentrations of hydrocortisone and nystatin would be equal to the maximum concentrations allowed by law for over the counter medications. These maximum concentrations are sufficient to facilitate in depth healing of the skin, but insufficient to effect more than topical coverage.
A method of treating fungal infections in skin tissue comprises the steps of providing an antifungal creme as specified described in the exemplary embodiments of the present invention, and applying the antifungal creme on the infected area of the skin.
Almost immediately, irritating symptoms associated with inflammation are relieved and disposition of the infection is facilitated by reducing swelling in the individual cells in the tissue. It has been found that this reduction in swelling unexpectedly substantially accelerates the penetration of the anti-fungal creme in the skin tissue.
The method of treating a diaper rash on an infant comprises the steps of providing an anti-fungal creme as described in the exemplary embodiments of the present invention and applying the anti-fungal creme on the rash. The symptoms associated with inflammation are relieved, and the healing of the rash is unexpectedly and substantially accelerated. This is because diaper rashes and irritation are not only caused by urine and feces, but can additionally result from fungal infection on the skin tissue.
Both the method of treating skin tissue and the method of treating a diaper rash can be utilized with all of the combinations of the components detailed above.
Examples Many of the following examples are given to illustrate various embodiments of the invention and should not be interpreted as limiting it in any way.
Example 1 The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about to 0.01 to about 2.5 percent by weight of said emollient base and said anti-fungal comprises from about 1 to about 500,000 units of nystatin per gram of said emollient base.
Example 2 The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about to 0.05 to about 2.0 percent by weight of said emollient base and said anti-fungal comprises from about 2500 to about 400,000 units of nystatin per gram of said emollient base.
Example 3 The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about to 0.1 to about 1.5 percent by weight of said emollient base and said anti-fungal comprises from about 25,000 to about 350,000 units of nystatin per gram of said emollient base.
Example 4 The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about to 0.5 to about 1.25 percent by weight of said emollient base and said anti-fungal comprises from about 200,000 to about 300,000 units of nystatin per gram of said emollient base.
Example 5 The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about 1.0 percent by weight of said emollient base and said anti-fungal comprises about 250,000 units of nystatin per gram of said emollient base.
It should be noted that ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a concentration range of "about 0.1% to about 5%" should be interpreted to include not only the explicitly recited concentration of about 0.1 wt% to about 5 wt%, but also the individual concentrations (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%) within the indicated range. The term "about"
can include 1%, 2%, 3%, 4%, 5%, 8%, or 10%, of the numerical value(s) being A
modified. In addition, the phrase "about `x' to `y"' includes "about `x' to about `y"'.
While the illustrative embodiments of the invention have been described with particularity, it will be understood that the invention is capable of other and different embodiments and that various other modifications will be apparent to and may be readily made by those skilled in the art without departing from the spirit and scope of the invention. Accordingly, it is not intended that the scope of the claims hereof be limited to the examples and descriptions set forth herein but rather that the claims be construed as encompassing all the features of patentable novelty which reside in the present disclosure, including all features which would be treated as equivalents thereof by those skilled in the art to which the invention pertains.
FIELD OF INVENTION
The present invention relates to a treatment for rashes and fungal infections.
More specifically, it relates to a creme, which is effective for the treatment of diaper rash and topical fungal infections.
BACKROUND OF INVENTION
Topical cremes are commonly used to treat fungal infections. However, many patients suffer from advanced topical fungal infections that are accompanied by irritating inflammatory conditions of pain, swelling and itching. Due to unknown and unidentified systemic conditions, a permanent cure is far from instantaneous, and in fact may be illusive for an extended period of time. Particularly, for these patients, in addition to treating fungal infections, it is desirable to treat accompanying inflammatory and irritant conditions of the skin to relieve pain, swelling and itching. The accompanying inflammation and irritation is the primary symptom, and most frequently it is the symptom itself, which is identified by the patient as the unresolved problem.
Diaper rashes are also a common problem encountered in infant and elderly care.
While there are many products that treat rashes, none also reduce the symptoms of the irritation.
There are numerous cremes that have been developed to treat either fungal infections or diaper rashes. However, none of these has proven effective for treating fungal infections, while also treating the inflammatory conditions of pain, swelling and itching that commonly accompany these fungal infections. Accordingly, there is a need for a topical fungal creme that meets this need.
SUMMARY OF THE INVENTION
The present invention relates to an antifungal and diaper rash treatment creme that is effective at treating fungal infections, while also treating the inflammatory conditions of pain, swelling and itching that commonly accompany these fungal infections.
I
The inventors of the present invention have found that one effective treatment for fungal infections is a polyene antifungal drug such as nystatin. Moreover, effective anti-inflammatory treatments include corticosteroids, such as hydrocortisone. It had previously been discovered that when an anti-fungal and an anti-inflammatory were applied consecutively, the combination was not optimally effective. This is because the first treatment prevents the direct absorption of the second treatment. The inventors of the present inventions have found that this problem can be overcome by applying the anti-fungal and the anti-inflammatory treatments in a single application.
The inventors of the present invention also discovered unexpected advantages when utilizing the correct formulation for the topical creme. It has been found that when a topical fungal infection is additionally treated with a corticosteroid, the curing of the infection is substantially and dramatically accelerated. Painful symptoms, which would otherwise persist for more than a few weeks were substantially reduced within 24 hours of application. For example, an individual with athlete's foot with considerable inflammation and discomfort would typically be healed in two to four weeks.
However, by utilizing the creme disclosed by the present invention, it has been found that individuals have been healed in less than two weeks.
The inventors of the present invention have also found that embodiments of the present invention are effective in treating diaper rashes. This is because the anti-fungal component of the present invention targets the fungi found in diaper rashes.
The fecal matter produced by the wearer of the diaper contain infections and the damp warm environment in a diaper is ideal for fungus growth. Commonly known diaper rash cremes do not treat the fungal infections involved with diaper rashes. In fact, many known cremes such as petroleum jelly can actually cover, and then contain the infection on the surface of the skin. Accordingly, a particular embodiment of the present invention includes an antifungal and diaper rash treatment creme for cells in skin tissue comprising:
a) a non-medicinal emollient base;
b) an anti-fungal in the emollient base to treat both obvious fungal infection as well as nonobvious fungal infection associated with diaper rash; and c) a corticosteroid in the emollient base to immediately reduce irritating symptoms of tissue congestion, and to thereby substantially accelerate infection disposition in obvious fungus treatment applications by facilitating penetration of less congested individual cells in the tissue by the anti-fungal.
In another embodiment of the present invention, the antifungal skin and diaper rash treatment creme comprises hydrocortisone in the amount of about to 0.01 to about 2.5 percent by weight of said emollient base and said anti-fungal comprises from about 1 to about 500,000 units of nystatin per gram of said emollient base.
In another embodiment of the present invention, the antifungal skin and diaper rash treatment creme comprises hydrocortisone in the amount of about to 0.05 to about 2.0 percent by weight of said emollient base and said anti-fungal comprises from about 2500 to about 400,000 units of nystatin per gram of said emollient base.
In another embodiment of the present invention, the antifungal skin and diaper rash treatment creme comprises hydrocortisone in the amount of about to 0.1 to about 1.5 percent by weight of said emollient base and said anti-fungal comprises from about 25,000 to about 350,000 units of nystatin per gram of said emollient base.
In another embodiment of the present invention, the antifungal skin and diaper rash treatment creme comprises hydrocortisone in the amount of about to 0.5 to about 1.25 percent by weight of said emollient base and said anti-fungal comprises from about 200,000 to about 300,000 units of nystatin per gram of said emollient base.
In another embodiment of the present invention, the antifungal skin and diaper rash treatment creme comprises hydrocortisone in the amount of about 1.0 percent by weight of said emollient base and said anti-fungal comprises about 250,000 units of nystatin per gram of said emollient base.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to an antifungal and diaper rash treatment creme that is effective at treating fungal infections, while also treating the inflammatory conditions of pain, swelling and itching that commonly accompany these fungal infections.
It will be readily understood that the components of the present invention, as generally described herein, could be arranged and designed in a wide variety of different formulations. Thus, the following more detailed description of the embodiments of the I
compositions or formulations of the present invention are not intended to limit the scope of the invention, as claimed, but are merely representative of the presently preferred embodiments of the invention.
In a particular embodiment of the present invention, an antifungal and diaper rash treatment creme for cells in skin tissue comprises a non-medicinal emollient base, an anti-fungal in the emollient base to treat both obvious fungal infection as well as nonobvious fungal infection associated with diaper rash and a corticosteroid in the emollient base to immediately reduce irritating symptoms of tissue congestion, and to thereby substantially accelerate infection disposition in obvious fungus treatment applications by facilitating penetration of less congested individual cells in the tissue by the anti-fungal.
It is noted that the emollient base might include such non-medicinal ingredients as aluminum hydroxide gel, ceteareith 15, monostearate, methylparaben, PEG-400, perfume, propylene glycol, propylparaben, purified water, simethicone emulsion, sodium hydroxide, sorbitol, titanium dioxide, white petroleum, cetearyl alcohol, ceteth 20, chlorocresol, mineral oil, sodium phosphate and other commonly used agents other than lanolin.
In a particular embodiment of the present invention, the corticosteroid comprises hydrocortisone in the amount of about 0.01 % to about 2.5% b weight of the emollient base and the anti-fungal comprises nystatin in the amount of 1-500,000 units per gram of the emollient base. In a preferred embodiment of the present invention, the hydrocortisone comprises I % of the emollient base, and wherein the nystatin generally comprises 250,000 units per gram of the emollient base. It is intended that in this embodiment, the concentrations of hydrocortisone and nystatin would be equal to the maximum concentrations allowed by law for over the counter medications. These maximum concentrations are sufficient to facilitate in depth healing of the skin, but insufficient to effect more than topical coverage.
A method of treating fungal infections in skin tissue comprises the steps of providing an antifungal creme as specified described in the exemplary embodiments of the present invention, and applying the antifungal creme on the infected area of the skin.
Almost immediately, irritating symptoms associated with inflammation are relieved and disposition of the infection is facilitated by reducing swelling in the individual cells in the tissue. It has been found that this reduction in swelling unexpectedly substantially accelerates the penetration of the anti-fungal creme in the skin tissue.
The method of treating a diaper rash on an infant comprises the steps of providing an anti-fungal creme as described in the exemplary embodiments of the present invention and applying the anti-fungal creme on the rash. The symptoms associated with inflammation are relieved, and the healing of the rash is unexpectedly and substantially accelerated. This is because diaper rashes and irritation are not only caused by urine and feces, but can additionally result from fungal infection on the skin tissue.
Both the method of treating skin tissue and the method of treating a diaper rash can be utilized with all of the combinations of the components detailed above.
Examples Many of the following examples are given to illustrate various embodiments of the invention and should not be interpreted as limiting it in any way.
Example 1 The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about to 0.01 to about 2.5 percent by weight of said emollient base and said anti-fungal comprises from about 1 to about 500,000 units of nystatin per gram of said emollient base.
Example 2 The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about to 0.05 to about 2.0 percent by weight of said emollient base and said anti-fungal comprises from about 2500 to about 400,000 units of nystatin per gram of said emollient base.
Example 3 The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about to 0.1 to about 1.5 percent by weight of said emollient base and said anti-fungal comprises from about 25,000 to about 350,000 units of nystatin per gram of said emollient base.
Example 4 The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about to 0.5 to about 1.25 percent by weight of said emollient base and said anti-fungal comprises from about 200,000 to about 300,000 units of nystatin per gram of said emollient base.
Example 5 The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about 1.0 percent by weight of said emollient base and said anti-fungal comprises about 250,000 units of nystatin per gram of said emollient base.
It should be noted that ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a concentration range of "about 0.1% to about 5%" should be interpreted to include not only the explicitly recited concentration of about 0.1 wt% to about 5 wt%, but also the individual concentrations (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%) within the indicated range. The term "about"
can include 1%, 2%, 3%, 4%, 5%, 8%, or 10%, of the numerical value(s) being A
modified. In addition, the phrase "about `x' to `y"' includes "about `x' to about `y"'.
While the illustrative embodiments of the invention have been described with particularity, it will be understood that the invention is capable of other and different embodiments and that various other modifications will be apparent to and may be readily made by those skilled in the art without departing from the spirit and scope of the invention. Accordingly, it is not intended that the scope of the claims hereof be limited to the examples and descriptions set forth herein but rather that the claims be construed as encompassing all the features of patentable novelty which reside in the present disclosure, including all features which would be treated as equivalents thereof by those skilled in the art to which the invention pertains.
Claims (6)
1. An antifungal and diaper rash treatment creme for cells in skin tissue comprising:
a) a non-medicinal emollient base;
b) an anti-fungal in said emollient base to treat both obvious fungal infection as well as nonobvious fungal infection associated with diaper rash; and c) a corticosteroid in said emollient base to immediately reduce irritating symptoms of tissue congestion, and to thereby substantially accelerate infection disposition in obvious fungus treatment applications by facilitating penetration of less congested individual cells in the tissue by the anti-fungal.
a) a non-medicinal emollient base;
b) an anti-fungal in said emollient base to treat both obvious fungal infection as well as nonobvious fungal infection associated with diaper rash; and c) a corticosteroid in said emollient base to immediately reduce irritating symptoms of tissue congestion, and to thereby substantially accelerate infection disposition in obvious fungus treatment applications by facilitating penetration of less congested individual cells in the tissue by the anti-fungal.
2. The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about to 0.01 to about 2.5 percent by weight of said emollient base and said anti-fungal comprises from about 1 to about 500,000 units of nystatin per gram of said emollient base.
3. The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about to 0.05 to about 2.0 percent by weight of said emollient base and said anti-fungal comprises from about 2500 to about 400,000 units of nystatin per gram of said emollient base.
4. The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about to 0.1 to about 1.5 percent by weight of said emollient base and said anti-fungal comprises from about 25,000 to about 350,000 units of nystatin per gram of said emollient base.
5. The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about to 0.5 to about 1.25 percent by weight of said emollient base and said anti-fungal comprises from about 200,000 to about 300,000 units of nystatin per gram of said emollient base.
6. The antifungal skin and diaper rash treatment creme of claim 1 wherein the corticosteroid comprises hydrocortisone in the amount of about 1.0 percent by weight of said emollient base and said anti-fungal comprises about 250,000 units of nystatin per gram of said emollient base.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2746717A CA2746717A1 (en) | 2011-07-18 | 2011-07-18 | Anti-fungal diaper rash creme |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2746717A CA2746717A1 (en) | 2011-07-18 | 2011-07-18 | Anti-fungal diaper rash creme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2746717A1 true CA2746717A1 (en) | 2013-01-18 |
Family
ID=47553762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2746717A Abandoned CA2746717A1 (en) | 2011-07-18 | 2011-07-18 | Anti-fungal diaper rash creme |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2746717A1 (en) |
-
2011
- 2011-07-18 CA CA2746717A patent/CA2746717A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004045572A1 (en) | Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil | |
| CA2822320A1 (en) | Composition for the treatment of skin conditions | |
| US6555125B2 (en) | Lesion and ulcer medication | |
| KR20110074513A (en) | Topical treatment of skin infection | |
| US5536502A (en) | Skin-tear medicament and method of use | |
| JP6842794B2 (en) | Topical skin preparation | |
| US6146640A (en) | Immune system catalyst | |
| US20080145461A1 (en) | Formulation and method of making a topical pain relief composition | |
| US20040151710A1 (en) | Topical composition for treating infectious conditions of skin and mucosa | |
| US5565189A (en) | Wound cleanser method of use | |
| MX2011009935A (en) | A medicinal cream for diaper rash and a process to make it. | |
| BR112016014601B1 (en) | dermatological composition, applicator device and method for preparing a dermatological composition | |
| US20230390176A1 (en) | Cosmetic Skin and Medical Cream | |
| DK2343038T3 (en) | Dermatological compositions containing a combination of peroxidized lipids and zinc and their use, especially for the treatment of herpes | |
| US8475852B2 (en) | Topical therapeautic composition and palliative treatment method | |
| CA2746717A1 (en) | Anti-fungal diaper rash creme | |
| US20110305785A1 (en) | Bulbine frutescens extract | |
| WO2017020036A1 (en) | Composition and related methods for treatment of pilosebaceous diseases | |
| RU2637092C1 (en) | Ointment for skin infections treatment | |
| US20140127315A1 (en) | Caudal Salve | |
| WO2016181355A1 (en) | Compositions for treating and/or preventing psoriasis, prickly heat, dermatitises, neurofibromatosis type 1 and other pathologies of the dermis, mucosae, and oral cavity | |
| NL1035426C2 (en) | Pharmaceutical compositions for the treatment of warts. | |
| RU2546030C1 (en) | Ichthyosin preparation | |
| JP6034386B2 (en) | Composition for application to the skin and use thereof | |
| US8741360B2 (en) | Topical therapeutic composition and palliative treatment method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20150609 |